|Awarded On||November 16, 2016|
|Title||A novel GRK3-EZH2 regulatory pathway in prostate cancer progression|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Wenliang Li|
|Cancer Sites||Lung and Bronchus, Prostate|
Prostate cancer (PCa) is a leading cause of cancer-related deaths for men. Androgen deprivation therapy (ADT) is the treatment of choice for advanced and metastatic PCa. Most patients respond to this treatment initially but the disease invariably recurs and becomes ADT-resistant. Frequently associated with ADT resistance is the emergence of neuroendocrine prostate cancers (NEPC) that have a poor prognosis with no effective treatment. With the recent introduction of potent ADT into clinic, the incidence of NEPC is expected to rise significantly. The objectives of this proposal are to obtain critical new insights in NEPC biology that is poorly understood, to identify new drug targets and to f...